{"id":14939,"date":"2021-01-05T01:23:07","date_gmt":"2021-01-04T22:23:07","guid":{"rendered":"https:\/\/www.klimikdergisi.org\/\/2021\/01\/05\/telaprevirli-uclu-tedavi-alan-53-kronik-hepatit-c-olgusunun-degerlendirilmesi\/"},"modified":"2021-01-05T01:23:07","modified_gmt":"2021-01-04T22:23:07","slug":"telaprevirli-uclu-tedavi-alan-53-kronik-hepatit-c-olgusunun-degerlendirilmesi","status":"publish","type":"post","link":"https:\/\/www.klimikdergisi.org\/tr\/2021\/01\/05\/telaprevirli-uclu-tedavi-alan-53-kronik-hepatit-c-olgusunun-degerlendirilmesi\/","title":{"rendered":"Telaprevirli \u00dc\u00e7l\u00fc Tedavi Alan 53 Kronik Hepatit C Olgusunun De\u011ferlendirilmesi"},"content":{"rendered":"<h1>\u00d6zet<\/h1>\n<p> <strong>Ama\u00e7<\/strong>: \u00c7al\u0131\u015fmam\u0131zda hepatit C virusu (HCV) genotip 1b infeksiyonu olan hastalar\u0131n telaprevir, pegile interferon ve ribavirin tedavisiyle elde edilen sonu\u00e7lar\u0131n\u0131 de\u011ferlendirmeyi ama\u00e7lad\u0131k.<\/p>\n<p> <strong>Y\u00f6ntemler<\/strong>: Gaziantep&#8217;te toplam be\u015f merkezde izlenen tedavi deneyimli 53 kronik hepatit C (KHC) hastas\u0131nda, telaprevir bazl\u0131 \u00fc\u00e7l\u00fc tedavinin sonu\u00e7lar\u0131 retrospektif olarak de\u011ferlendirildi. Demografik veriler, tedaviye ba\u011fl\u0131 yan etkiler, tedavi indikasyonlar\u0131, kal\u0131c\u0131 virolojik yan\u0131t (KVY) oranlar\u0131 ve sonu\u00e7lar\u0131 kaydedildi.<\/p>\n<p> <strong>Bulgular<\/strong>: \u00c7al\u0131\u015fmaya al\u0131nan HCV genotip 1b infeksiyonu olan 53 hastadan 43 (%81.1)\u2019\u00fc tedavi s\u00fcresini tamamlayabildi. Tedavi edilenlerin 44 (%83)\u2019\u00fc n\u00fcks, 9 (%17)\u2019u yan\u0131ts\u0131z hasta gruplar\u0131ndand\u0131. Telaprevir bazl\u0131 \u00fc\u00e7l\u00fc tedaviyle 31 (%58.5) hastada KVY geli\u015fti. Ka\u015f\u0131nt\u0131, deri d\u00f6k\u00fcnt\u00fcs\u00fc, anemi ve anorektal yak\u0131nmalar g\u00f6zlenen ba\u015fl\u0131ca yan etkilerdi. 19 hastada eritrosit s\u00fcspansiyonu transf\u00fczyonu yap\u0131l\u0131rken, 13 hastada ribavirin dozu azalt\u0131ld\u0131. \u015eiddetli yan etkilerden dolay\u0131 10 (% 18.9) hasta tedaviyi tamamlayamad\u0131.<\/p>\n<p> <strong>Sonu\u00e7lar<\/strong>: \u015eiddetli ve s\u0131k g\u00f6r\u00fclen yan etkilerine kar\u015f\u0131n, telaprevir bazl\u0131 tedavi, yeni direkt etkili antiviral ajanlar\u0131n \u00f6ncesindeki d\u00f6nemde, hem n\u00fcks hem de yan\u0131ts\u0131z hasta gruplar\u0131 i\u00e7in KHC hastalar\u0131n\u0131n yar\u0131dan fazlas\u0131nda KVY sa\u011flam\u0131\u015ft\u0131r.\u00a0<\/p>\n<p> Klimik Dergisi 2017; 30(3): 126-30.<\/p>\n<p> <strong>Cite this article as<\/strong>: \u015eahin A, Bayram H, Nam\u0131duru M, et al. [Evaluation of 53 cases with chronic hepatitis C receiving telaprevir-based triple therapy]. Klimik Derg. 2017; 30(3): 126-30. Turkish.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00d6zet Ama\u00e7: \u00c7al\u0131\u015fmam\u0131zda hepatit C virusu (HCV) genotip 1b infeksiyonu olan hastalar\u0131n telaprevir, pegile interferon ve ribavirin tedavisiyle elde edilen sonu\u00e7lar\u0131n\u0131 de\u011ferlendirmeyi ama\u00e7lad\u0131k. Y\u00f6ntemler: Gaziantep&#8217;te toplam be\u015f merkezde izlenen tedavi deneyimli 53 kronik hepatit C (KHC) hastas\u0131nda, telaprevir bazl\u0131 \u00fc\u00e7l\u00fc tedavinin sonu\u00e7lar\u0131 retrospektif olarak de\u011ferlendirildi. Demografik veriler, tedaviye ba\u011fl\u0131 yan etkiler, tedavi indikasyonlar\u0131, kal\u0131c\u0131 virolojik [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5129],"tags":[4643,2580,4454],"class_list":["post-14939","post","type-post","status-publish","format-standard","hentry","category-ozgun-arastirma","tag-gaziantep","tag-hepatit-c-virusu","tag-telaprevir"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/posts\/14939","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/comments?post=14939"}],"version-history":[{"count":0,"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/posts\/14939\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/media?parent=14939"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/categories?post=14939"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/tags?post=14939"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}